N. G. R. Dayan Elshan

This study evaluates CMX990, a coronavirus Mpro inhibitor, showing broad antiviral activity against multiple coronaviruses and superior pharmacologic properties compared to existing inhibitors.

This paper describes the development of orally bioavailable SARS-CoV-2 protease inhibitors with a hydroxymethyl ketone warhead, showing improved potency and bioavailability compared to previous compounds.

This study identifies sCMF231, a small molecule that activates YAP by inhibiting FUBI-mediated fubylation of Annexin A2, thereby enhancing YAP transcriptional activity.